载药微球在肝动脉化疗栓塞术中对原发性肝癌患者的疗效观察OACSTPCD

Objective:To compare the efficacy between drug-loaded CalliSpheres transcatheter arterial chemo-embolization(D-TACE)and the conventional transcatheter arterial chemoembolization(C-TACE)in patients with primary hepatocarcinoma.Methods:The medical records of 95 patients with liver cancer treated with D-TACE from January 2019 to December 2021 in the Guangxi Medical University Cancer Hospital were retrospec-tively analyzed.According to the application of D-TACE,the patients were divided into D-TACE group(observa-tion group,44 cases)and C-TACE group(control group,51 cases).The clinical efficacy was observed 3 months after treatment.The liver function indexes were evaluated by checking alanine aminotransferase(ALT),aspartate aminotransferase(AST),total bilirubin(TBIL),albumin(ALB),alpha-fetoprotein(AFP),electrolyte potassium(K),calcium(Ca),magnesium(Mg),and liver cancer cell viability.The short-term clinical efficacy and adverse reactions of the two groups were observed and followed up for 12 months.Results:After treatment,AFP levels in both groups were lower than before treatment,and the level of AFP in the observation group was significantly lower than that in the control group after treatment(P＜0.01).The disease control rates of observation group and control group were 88.63%and 70.59%,respectively,with statistically significant differences between the groups(P＜0.05).There was no statistical significance in complications between the two groups(P＞0.05).The 12-month survival rate of the observation group was higher than that of the control group(P＜0.05).The grades of Child-Pugh,the number of tumors,the level of AFP,and the use of drug-loaded CalliSpheres were closely related to the prognosis of the patient's overall survival.Conclusion:D-TACE has better short-term efficacy than C-TACE in the treatment of primary hepatocarcinoma,and has good safety and prognosis.